GleamWall
中文EN

PLRX PLIANT THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1746473 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY48.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.3%
ROA-40.5%
ROIC (approx.)-63.7%
Asset turnover—

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.00x
Current ratio8.05x
Interest coverage-698.18x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$109.16M$169.31M
SG&A expense$47.22M$59.05M
Operating income-$156.37M-$228.37M
Interest expense$2.56M$3.02M
Pretax income-$149.30M-$210.30M
Income tax$0$0
Net income-$149.34M-$210.30M
EBITDA-$154.68M-$226.24M
EPS (basic)-2.43-3.47
EPS (diluted)-2.43-3.47
Dividends declared per share0.000.00
Weighted avg. shares (diluted)61.37M60.54M
Balance sheet
Cash & equivalents$45.45M$72.67M
Short-term investments$145.50M$284.54M
Current assets$196.45M$362.26M
PP&E, net$2.94M$5.53M
Total assets$225.23M$396.95M
Current liabilities$16.36M$33.22M
Long-term debt$0$30.21M
Total debt$0$30.21M
Total liabilities$44.02M$92.87M
Shareholders' equity$181.21M$304.08M
Net debt-$45.45M-$42.46M
Shares outstanding61.45M60.86M
Cash flow statement
Operating cash flow-$128.34M-$155.50M
Capital expenditure$374,000$3.85M
Free cash flow-$128.71M-$159.35M
Investing cash flow$134.29M$140.34M
Financing cash flow-$31.70M$23.12M
Depreciation & amortization$1.70M$2.12M
Stock-based compensation$26.23M$37.63M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.